Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT

Nursing and Health Professions

• Diseases 100%
• Patient 100%
• Standard 100%
• Placebo 100%
• Opiate 100%
• Naltrexone 100%
• Diamorphine 33%
• Drug 27%
• Sample 16%
• Relapse 16%
• Combination Therapy 11%
• Time 11%
• Electric Potential 11%
• Adult 11%
• Drug Therapy 11%
• Implant 11%
• Obstetric Delivery 11%
• Self Report 11%
• Cooling 11%
• Outpatient 11%
• Study Participant 11%
• Biomedical Technology Assessment 11%
• Hospital 5%
• Prevention 5%
• Cost Effectiveness Analysis 5%
• Clinical Practice 5%
• Medical Specialist 5%
• Randomization 5%
• Addiction 5%
• Detoxication 5%
• Clinical Effectiveness 5%
• Group Therapy 5%
• Tablet 5%
• Heroin Dependence 5%
• Opiate Antagonist 5%

Medicine and Dentistry

• Placebo 100%
• Arm 100%
• Naltrexone 100%
• Opioid Abuse 100%
• Diamorphine 33%
• Chemotherapeutic Agent 27%
• Drug 27%
• Urine 27%
• Therapeutic Procedure 22%
• Health 11%
• Amaurosis 11%
• Obstetric Delivery 11%
• Relapse 11%
• Consent 11%
• Self Report 11%
• Combination Therapy 5%
• Drug Therapy 5%
• Technology Assessment 5%
• Medication 5%
• Substance Use Disorder 5%
• Cost-Effectiveness Analysis 5%
• Addictive Behavior 5%
• Group Therapy 5%
• Detoxication 5%
• Abstinence 5%
• Relapse Prevention 5%
• Opiate Antagonist 5%
• Health Technology 5%
• Heroin Dependence 5%
• Assessment in Health Technology 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Diseases 100%
• Opiate 100%
• Randomized Controlled Trial 100%
• Naltrexone 100%
• Diamorphine 33%
• Drug 27%
• Implant 22%
• Relapse 16%
• Blindness 11%
• Intervention Study 11%
• Detoxification 5%
• Addiction 5%
• Tablet 5%
• Drug Dependence 5%
• Opioid Antagonist 5%
• Heroin Dependence 5%